Arcellx, Inc. (ACLX)
Largest Insider Buys in Sector
ACLX Stock Price History Chart
ACLX Stock Performance
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid …
Insider Activity of Arcellx, Inc.
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $69.07M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $182.5M and sold $64.58M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
List of Insider Buy and Sell Transactions, Arcellx, Inc.
| 2024-12-03 | Sale | director | 1,500 0.0028% | $91.88 | $137,818 | -5.90% | ||
| 2024-11-15 | Sale | CHIEF FINANCIAL OFFICER | 1,761 0.003% | $88.87 | $156,508 | -1.29% | ||
| 2024-11-12 | Sale | director | 1,500 0.0029% | $106.33 | $159,495 | -13.32% | ||
| 2024-11-11 | Sale | director | 15,238 0.0283% | $105.92 | $1.61M | -18.13% | ||
| 2024-11-08 | Sale | director | 7,976 0.0142% | $99.85 | $796,426 | -15.37% | ||
| 2024-11-08 | Sale | CHIEF FINANCIAL OFFICER | 12,354 0.0222% | $100.55 | $1.24M | -15.37% | ||
| 2024-11-08 | Sale | director | 33,763 0.0629% | $104.14 | $3.52M | -15.37% | ||
| 2024-11-07 | Sale | director | 8,478 0.0158% | $99.30 | $841,861 | -12.04% | ||
| 2024-10-22 | Sale | director | 1,500 0.0028% | $89.69 | $134,535 | 0.00% | ||
| 2024-10-01 | Sale | director | 1,500 0.0027% | $82.24 | $123,360 | +6.70% | ||
| 2024-09-17 | Sale | CHIEF FINANCIAL OFFICER | 15,000 0.0278% | $77.73 | $1.17M | +10.83% | ||
| 2024-09-10 | Sale | director | 1,500 0.0028% | $74.41 | $111,615 | +16.19% | ||
| 2024-09-05 | Sale | CHIEF MEDICAL OFFICER | 3,421 0.0063% | $70.02 | $239,526 | +22.32% | ||
| 2024-09-03 | Sale | CHIEF MEDICAL OFFICER | 27,451 0.0518% | $67.03 | $1.84M | +29.94% | ||
| 2024-08-26 | Sale | CHIEF MEDICAL OFFICER | 21,684 0.0399% | $71.13 | $1.54M | +17.59% | ||
| 2024-08-20 | Sale | director | 1,500 0.0028% | $65.88 | $98,820 | +27.18% | ||
| 2024-08-16 | Sale | CHIEF MEDICAL OFFICER | 5,450 0.0112% | $65.05 | $354,526 | +2.03% | ||
| 2024-08-01 | Sale | CHIEF MEDICAL OFFICER | 20,000 0.0385% | $60.42 | $1.21M | +41.42% | ||
| 2024-07-30 | Sale | director | 1,500 0.0028% | $61.97 | $92,949 | -5.35% | ||
| 2024-07-16 | Sale | CHIEF MEDICAL OFFICER | 10,901 0.0248% | $65.30 | $711,854 | +24.62% |
Insider Historical Profitability
| Carroll Jill | director | 1479148 2.7354% | $75.54 | 1 | 6 | +6.58% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.474% | $75.54 | 2 | 0 | +40.21% |
| Novo Holdings A/S | 10 percent owner | 4016878 7.4284% | $75.54 | 1 | 0 | +6.58% |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 3.0676% | $75.54 | 1 | 1 | +6.58% |
| BASKETT FOREST | director | 0 0% | $75.54 | 1 | 1 | +73.84% |
Institutional Investor Ownership
| Fidelity Investments | $375.19M | 10.08 | 5.39M | +23.18% | +$70.62M | 0.03 | |
| Perceptive Advisors | $273.58M | 7.35 | 3.93M | -13.45% | -$42.51M | 0.18 | |
| Paradigm BioCapital Advisors LP | $265.55M | 7.14 | 3.82M | +4.36% | +$11.09M | 9.63 | |
| Nea Management Company Llc | $260.48M | 7 | 3.75M | 0% | +$0 | 1.22 | |
| BlackRock | $213.25M | 5.73 | 3.07M | +1.57% | +$3.31M | 0.01 |